New Strategies for Reducing Cardiovascular Risk in CKD with T2D: Development of Finer Mineralocorticoid Antagonists

FACULTY

George Bakris, MD, FASH, FASN, FAHA
Professor of Medicine
Director, American Heart Association Comprehensive Hypertension Center
University of Chicago Medicine
Chicago, IL

Robert Toto, MD
Medical Director of the Multi-Specialty Clinic at UT Southwestern Medical Center
Associate Dean of Clinical and Translational Research in the Graduate School of Biomedical Sciences
Director of the Center for Translational Medicine
Medical Director of UT Southwestern’s Multi-Specialty Clinic

PROGRAM OVERVIEW

In this comprehensive and interactive CME activity, we will be presenting important topics in the area of diabetic kidney disease. The program includes slide-based material interspersed with interactive questions and case studies to enhance learning. The focus is on kidney disease in the diabetic patient, specifically mechanisms of disease, diagnosis and evaluation, and therapeutic options.

TARGET AUDIENCE

This activity is designed to meet the educational needs of cardiologists and other healthcare practitioners to ensure recognition of CKD risk in patients with T2D and novel strategies for modifying cardiovascular and renal risk in patients with T2D.

LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

  • Review the mechanistic features of novel mineralocorticoid receptor antagonists and differentiate these therapies from earlier mineralocorticoid receptor antagonists
  • Evaluate CKD risk in patients with T2D and clinical data with novel mineralocorticoid receptor antagonists to manage the risk of renal deterioration
  • Summarize strategies for the management of hyperkalemia in patients receiving mineralocorticoid receptor antagonists

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the virtual enduring activity.

Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with chronic kidney disease.
CNE Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Dr. George Bakris is a consultant for Merck, Bayer, Vifor Pharma, Ionis, Alnylam, Astra Zeneca, Horizon, and Bayer. He has received grant/clinical trials research support from Bayer, Quantum Genomics, DiaMedica Therapeutics, and Novo Nordisk.

Dr. Robert Toto has worked as a consultant for Boehringer-Ingelheim, Bayer, Reaata, Medscape, ACI, Vifor, and AstraZeneca. He also received contracted research fees from NIH.

CME Content Review

The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer reviewed by a nurse reviewer.

Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.

INSTRUCTIONS FOR PARTICIPATION AND CREDIT

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Read the CME/CE information and faculty disclosures.
  2. Participate in the enduring activity.
  3. Submit the evaluation form.

You will receive your certificate on program completion.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

 

Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Scroll to Top

A Special Thank You to All HCPs

Med Learning Group sends its heartful gratitude to all healthcare professionals giving their all, 24/7, during this pandemic, despite the great risks they face. We cannot thank you enough for your courage and selfless service.

Connecting you with our personalized approach to continuing Medical Education

The Linking Approach to Education from Gap Analysis to Outcomes

Med Learning Group, a division of Ultimate Medical Academy, is a full-service accredited medical education company with commendation. Med Learning Group focuses on developing and implementing continuing education that improves healthcare practitioners’ ability to provide optimal care to their patients. Our goal is to provide high-quality education that is designed to deliver the highest level of outcomes for not only the practitioner, but also the patient. Med Learning Group has expertise in developing both live and online activities that are innovative, case-based, interactive and patient-centric in nature.

Med Learning Group has expertise in developing both live and online activities that are innovative, case-based, interactive and patient-centric in nature, and we focus on applying adult learning theory and principles to our programs. Even more importantly, we understand the nuances of our target audiences and design programs with a grounded understanding of how to educate both specialty audiences and general practitioners.